Visceral pain
Visceral pain is defined as pain that results from the activation of nociceptors of the thoracic, pelvic, or abdominal viscera in the human body. Visceral structures are highly sensitive to distension, ischemia and inflammation, but relatively insensitive to other stimuli that normally evoke pain such as cutting or burning.
Visceral pain is diffuse, difficult to localize, and often referred to a distant, usually superficial, structure. It may be accompanied by symptoms such as nausea, vomiting, changes in vital signs as well as emotional manifestations. The pain may be described as sickening, throbbing, pulsating, deep, squeezing, and/or dull.
Physiology
Nociceptive innervation
Nociceptive innervation is often the only type of sensory innervation possessed by visceral structures. Nociceptive innervation of visceral structures entails two distinct modalities:- The actual viscera possess sparse nociceptive innervation via "slow" group C nerve fibers which are bundled into autonomic nerves to be conveyed to the spinal cord segments where the organ which they innervate originally arose during embryological development; in the spinal cord, the central branch of the visceral nociceptive neuron then synapses with multiple 2nd-order nociceptive neurons which also receive nociceptive stimuli from 1st-order nociceptive neurons innervating the skin. Consequently, true visceral pain is perceived as dull chronic pain referred to the dermatomes of the body surface innervated by nociceptive neurons from the same spinal cord segments as the embryologic origin of the affected organ. Due to the sparse innervation, highly localised insults tends to be relatively or completely painless, whereas insults that cause diffuse activation of visceral nociceptive produce intense suffering.
- Parietal surfaces possess abundant nociceptive innervation directly from local spinal nerves. Parietal pain is thus typically experienced as having a sharp quality and perceived directly over the affected visceral area, and may be evoked by a local insult like an incision.
The liver parenchyma and lung alveoli are virtually free of nociceptive innervation; nevertheless, bile ducts and the connective tissue covering of the liver are sensitive to pain, as are the bronchi and parietal pleura.
Mechanisms
Visceral pain may be evoked by:- tissue ischaemia,
- chemical insults to visceral surfaces,
- spasm of smooth muscle in the walls of hollow viscera - pain may be mediated either by direct mechanical stimulation of nociceptors, or by decreased perfusion and increased metabolic rate of actively contracting muscle; pain caused by spasmatic contraction of smooth muscle of hollow viscera is often experienced as cramp-like and as waxing and waning - as each peristaltic wave causes a spasm of a hyperecticable region of smooth muscle upon reaching it,
- excessive distension of a hollow viscera - possibly by overstretching of nociceptive fibres, or compression of blood vessels to cause ischaemia,
- extension of the connective tissues upon or within visceral organs.
Visceral hyperalgesia
Inflammation, or repetitive or prolongued exposure to non-noxious stimuli may render viscera hyperalgesic, lowering the pain threshold of affected viscera. For example, repetitive experimental filling of the distal colon of human subjects initially produces distension that is perceived as painless, but the same distension subsequently comes to be experienced as painful. Such hyperalgesia may underlie pain experienced in certain clinical conditions like inflammatory bowel disease and may thus also represent a therapeutic target.Clinical presentation
Visceral pain is one of the main presenting complaints of patients and is frequently encountered in the clinical setting. True visceral pain.Visceral pain is typically associated with autonomic symptoms. Strong emotional reactions are also common presenting signs and may include anxiety, anguish and a sense of impending doom.
Importantly, perceived intensity of pain may often be unrelated to the actual clinical severity of the underlying pathology causing the pain. More rarely, intense visceral pain may be associated with a more innocuous aetiology.
The dermatomes experiencing referred pain may become affected by secondary hyperalgesia - especially when the causative visceral pain has been recurrent or chronic. Secondary hyperalgesia may persist after the underlying condition has been resolved.
Progression
Milder incohate true visceral pain can be perceived as vague malaise and discomfort, accompanied by autonomic signs and emotional distress, and localised indistinctly to the midline lower sternal region or epigastrium regardless of the underlying aetiology. With the onset of referred pain, the autonomic and emotional symptoms abate.Treatment
There are two goals when treating visceral pain:- to alleviate the current experience of pain and
- to address any underlying pathology, if and when identifiable.
Symptomatic treatment of visceral pain relies primarily upon pharmacotherapy. Since visceral pain can result secondary to a wide variety of causes, with or without associated pathology, a wide variety of pharmacological classes of drugs are used including a variety of analgesics, antispasmodics, antidepressants as well as others. In addition, pharmacotherapy that targets the underlying cause of the pain can help alleviate symptoms due to lessening visceral nociceptive inputs. For example, the use of nitrates can reduce anginal pain by dilating the coronary arteries and thus reducing the ischemia causing the pain. The use of spasmolytics can help alleviate pain from a gastrointestinal obstruction by inhibiting the contraction of the gut. There are issues associated with pharmacotherapy that include side effects, chemical dependence or addiction, and inadequate pain relief.
Invasive therapies are in general reserved for patients in whom pharmacological and other non-invasive therapies are ineffective. A wide variety of interventions are available and shown to be effective, a few will be discussed here. Approximately 50–80% of pelvic cancer pain patients benefit from nerve blocks. Nerve blocks offer temporary relief and typically involve injection of a nerve bundle with either a local anesthetic, a steroid, or both. Permanent nerve block can be produced by destruction of nerve tissue. Strong evidence from multiple randomized controlled trials support the use of neurolytic celiac plexus block to alleviate pain and reduce opioid consumption in patients with malignant pain originating from abdominal viscera such as the pancreas. Neurostimulation, from a device such as a spinal cord stimulator, for refractory angina has been shown to be effective in several randomized controlled trials. A SCS may also be used for other chronic pain conditions such as chronic pancreatitis and familial Mediterranean fever. Other devices that have shown benefit in reducing pain include transcutaneous electrical nerve stimulators, targeted field stimulation, both used for somatic hyperalgesic states, external neuromodulation, pulsed radiofrequency ablation and neuraxial drug delivery systems.